Skip to content
Peptide.Guide
ClinicalGLP-1 & IncretinSubQWeeklyPartial data

Cagrilintide

AM833

Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).

Read dosing protocol

§ 01   Overview

Overview

Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).

Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.

§ 02   Mechanism

Mechanism of action

Cagrilintide is an acylated amylin analog with extended half-life. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and increase satiety via area postrema signaling.

  • 01Additive weight loss when combined with GLP-1 agonists
  • 02Reduced food cravings and portion size
  • 03Preserved lean mass in some trials

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
0.16 – 2.4 mg weekly
Route
SubQ
Frequency
Weekly
Cycle
Titrate alongside GLP-1 if stacked.

§ 04   Evidence

Evidence & research

Clinical

Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.

FDA Status

Investigational as monotherapy; CagriSema in Phase III.

§ 05   Stacks

Common stacks

Semaglutide

Forms CagriSema

Tirzepatide

Off-label stacking

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Investigational, no compounding path

Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.

International · 1

International

Trident Peptides

1,299+ Trustpilot reviews (5-star). Strongest review base in UK research peptides. No visible ISO/GMP; COAs not posted.

1 flag on record
Visit

Research-use-only · 2

Research-use-only

Swiss Chems

Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.

Third-Party Testing1 flag on record
Visit
Research-use-only

Summit Research

FDA warning letter December 2024 across multiple GLP-1s.

1 flag on record

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Nausea
  • 02Appetite suppression can be substantial

Contraindications

None specified.

◆   In this categoryMore from GLP-1 & Incretin
01

Semaglutide

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with established cardiovascular benefit.

Established
02

Tirzepatide

Dual GIP/GLP-1 receptor agonist producing greater average weight loss than semaglutide in head-to-head trials.

Established
03

Retatrutide

Investigational triple agonist (GLP-1, GIP, glucagon) producing the largest weight loss seen in Phase II trials to date.

Clinical
04

Mazdutide

Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.

Clinical
05

Oral GLP Compound (ER-ORF)

Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.

Clinical

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.